Caris Life Sciences, Inc. (CAI)

Caris Life Sciences stands out for its broad molecular and AI-driven cancer diagnostics but faces upcoming volatility as the IPO lock-up expires on 15 December 2025. CAI's revenue growth is robust, driven primarily by molecular profiling, but overdependence on this segment and execution across diverse fronts pose risks. The company boasts industry-leading breadth—tissue and blood testing, early detection, monitoring, and biopharma partnerships—but faces strong, focused competitors in each segment.

IRVING, Texas , Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek®. This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies.

IRVING, Texas , Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients. The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor (HR)-positive, helping them stay on treatment longer than those taking SG, across all HER2-negative groups.

IRVING, Texas , Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported total revenue of $181.4 million, an increase of 81.3% over the corresponding prior year period.

Groundbreaking study in Nature Communications highlights AI's role in transforming immunotherapy decisions and precision oncology IRVING, Texas , Aug. 6, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a new study in Communications Medicine, a Nature portfolio journal, demonstrating that Caris' AI-based image analysis model has the potential to more accurately predict cancer biomarkers and patient survival than the conventional companion diagnostic (CDx) methods. By analyzing hematoxylin and eosin (H&E) images, the study demonstrated that Caris' AI model can improve the assessment of critical cancer biomarkers and impact patient survival outcomes in breast and colorectal cancers.

Caris GPSai™ utilizes deep learning to significantly improve diagnostic accuracy for cancers of unknown primary and misclassified tumors IRVING, Texas , Aug. 5, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, recently published a study on the development and validation of Caris' latest version of Caris GPSai™ in AACR's Cancer Research Communications Journal. Caris GPSai is a clinically validated deep learning multi-layer AI that leverages comprehensive whole exome and whole transcriptome sequencing (WES/WTS) to significantly improve diagnostic accuracy for cancers of unknown primary (CUP) and identify patients who have potentially misdiagnosed tumors.

IRVING, Texas , July 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m.

Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas , July 22, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published original data in the New England Journal of Medicine independently validating recent findings on tumor-infiltrating clonal hematopoiesis (TI-CH), and further reinforcing its leadership in precision oncology.    As a champion of scientific collaboration, Caris appreciated the opportunity to validate a recent study published in the New England Journal of Medicine, which brought attention to the clinical challenge of TI-CH—blood-derived mutations that infiltrate tumor tissue and are often misinterpreted as tumor-specific mutations.

Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas , July 8, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal, demonstrating the accuracy and clinical utility of the Caris Assure® blood-based biopsy assay across the cancer continuum.

A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine, but remains deeply unprofitable despite narrowing losses. The IPO was strong, with shares surging post-offering and the company now trading at a steep 15-16x sales multiple, reflecting high investor expectations. While revenue growth is impressive and losses are shrinking, the valuation is too rich for my taste, given the ongoing substantial losses and business risks.

Live Updates Live Coverage Has Ended IPO Soars 12:56 pm by Gerelyn Terzo The markets embraced healthcare newcomer Caris Life Sciences (Nasdaq: CAI) today, marking its debut on the Nasdaq. After pricing its initial public offering at $21 per share, Caris Life skyrocketed, rising over 32% to hit $27.85 per share. The company is at the forefront of medical innovation, harnessing AI algorithms in blood tests to diagnose early detection of diseases like breast cancer. The SPY ETF is now up 0.35%. Rising Stocks 11:23 am by Gerelyn Terzo Hasbro (Nasdaq: HAS) shares are up 1.3% today. The toymaker is undertaking a restructuring, resulting in the layoff of 3% of its workforce, a move attributed to the impact of tariffs. Circle (NYSE: CRCL) is surging 16% today, buoyed by the passage of stablecoin-friendly legislation in Congress. Magnificent 7 stock Amazon (Nasdaq: AMZN) is up 0.88% after CEO Andy Jassy projected that artificial intelligence will reshape the corporate workforce in the not-too-distant future, as the e-commerce titan increasingly leans on technology. Housing Market Teetering 10:20 am by Gerelyn Terzo Cracks are increasingly beginning to show in the U.S. housing market. New home construction activity tumbled last month, with housing starts plummeting by nearly 10% to their lowest level in five years. New home construction declined by 9.8% to an annualized rate of 1.26 million starts, reflecting a softening in demand from homebuyers. Looking ahead, a potential harbinger of future activity, building permits also slipped, falling 2% from April levels to a pace of 1.39 million. The SPY ETF has widened its lead to a 0.51% gain. This article will be updated throughout the day, so check back often for more daily updates. The markets are managing gains even as Middle East tensions mount and the geopolitical net potentially draws in the U.S. Indeed, stocks are largely holding their ground ahead of the Federal Reserve’s looming decision on interest rates. As President Trump assesses his strategy, the price of oil has surged to levels not seen in months, now hovering above $73 per barrel. Encouragingly, most sectors of the economy are seeing gains this morning, and the S&P 500 is within striking distance (less than 3%) of its latest all-time high. Today, the SPDR S&P 500 ETF (SPY) is up 0.32%. The Fed’s latest decision on interest rates is expected this afternoon, and the prevailing sentiment is that policymakers will leave rates unchanged, much to President Trump’s disliking. Here’s a look at the performance as of morning trading: Dow Jones Industrial Average: Up 113.94 (+0.28%) Nasdaq Composite: Up 83.12 (+0.43%) S&P 500: Up 21.75 (+0.36%) Winners & Losers JPMorgan is casting a favorable eye on fintech stocks, which are rivals to traditional financial institutions. The analyst firm has highlighted Q2 Holdings (NYSE: QTWO), nCino (Nasdaq: NCNO), and Alkami (Nasdaq: ALKT), adding them to a list of companies poised to capitalize on the digital banking revolution. JPMorgan is labeling the sector an “attractive investment arena.” All three of these names are posting gains today. Meanwhile, Solar Stocks like Enphase Energy (Nasdaq: ENPH) and First Solar (Nasdaq: FSLR) are facing headwinds. They’re under pressure following efforts in Washington, D.C. to potentially strip out a renewable energy tax credit from the upcoming tax bill. The post S&P 500 (NYSEARCA: SPY) Live: Markets Withstand Unrelenting Mideast Pressure, Rate Decision appeared first on 24/7 Wall St..

Live Updates Live Coverage Updates appear automatically as they are published. Today's IPO Receives Warm Welcome 12:53 pm by Gerelyn Terzo The markets rolled out the welcome mat for healthcare stock Caris Life Sciences (Nasdaq: CAI) today, which makes its debut on the Nasdaq. After pricing the IPO at $21 per share, Caris Life has climbed over 32% to $27.85 per share. Caris Life uses AI algorithms in blood tests to diagnose early detection of diseases like breast cancer. The Nasdaq Composite is up 0.47%. Market Gainers 11:17 am by Gerelyn Terzo Hasbro (Nasdaq: HAS) stock is up 1.3% today. The toymaker announced a restructuring in which it is laying off 3% of its workforce due to the impact of the tariffs. Circle (NYSE: CRCL) is soaring 16% today on the heels of stablecoin-friendly legislation that was passed by Congress. Amazon (Nasdaq: AMZN) is up 0.88% today after CEO Andy Jassy forecast that AI would replace more of the corporate workforce in the not-too-distant future as the e-commerce giant ramps up its dependance on technology. Housing Market Weakness 9:52 am by Gerelyn Terzo Housing starts, which reflect the level of new home construction activity, sank by close to 10% last month to their worst level since the pandemic era. New home construction fell 9.8% to 1.26 million starts in response to waning demand from homebuyers. In a sign of things to come, building permits almost moved lower, falling 2% vs. April levels to a pace of 1.39 million. The Nasdaq Composite remains in the green, rising 0.14%. This article will be updated throughout the day, so check back often for more daily updates. The markets continue to put on a brave face even as Middle East tensions escalate and the net widens to potentially involve the U.S. Stocks are holding their own ahead of the Fed’s decision on interest rates. The major stock market averages, including the Nasdaq Composite, are showing little direction amid an uncertain backdrop. While President Trump is strategizing his next move, the price of oil has soared to multi-month highs to hover above $73 per barrel. Most sectors of the economy are trading higher this morning. Despite the market volatility and geopolitical headwinds, the broader market (S&P 500 index) is within a stone’s throw – 2.6% – of fresh all-time high levels. The Fed’s decision on interest rates is imminent, and the markets appear to have priced in the likelihood that rates will remain unchanged. A decision is expected by mid-afternoon. Here’s a look at the performance as of morning trading: Dow Jones Industrial Average: Up 54.67 (+0.13%) Nasdaq Composite: Up 8.08 (+0.04%) S&P 500: Up 4.68 (+0.08%) Market Movers JPMorgan is bullish on fintech stocks, which incidentally serve as competition to traditional financial institutions. The analyst firm has added Q2 Holdings (NYSE: QTWO), nCino (Nasdaq: NCNO) and Alkami (Nasdaq: ALKT) to its list of stock that are poised to benefit from the digital banking era, calling the sector an “attractive investment arena.” All three of these stocks are rising higher today. Solar Stocks like Enphase Energy (Nasdaq: ENPH) and First Solar (Nasdaq: FSLR) are under pressure due to a push in Washington, D.C. to remove a renewable energy tax credit in the new tax bill. The post Live Nasdaq Composite: Markets Hold Steady on Fed Day as Mideast Tensions Boil appeared first on 24/7 Wall St..

On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering.

Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company's business of molecular profiling and drug research using artificial intelligence.

The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was priced at $21 a share. The stock was recently up 26% and trading at $26.48.